Palisade Bio (PALI) Cash from Operations Growth (1y) (2011 - 2026)
Palisade Bio (PALI) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 158.60% |
| 10 | Palisade Bio | 418.57 Mn | 285.95 Mn | - | -66.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.74% |
| Dec 31, 2025 | -32.05% |
| Sep 30, 2025 | -13.41% |
| Jun 30, 2025 | 48.07% |
| Mar 31, 2025 | 26.64% |
| Dec 31, 2024 | 13.29% |
| Sep 30, 2024 | -17.69% |
| Jun 30, 2024 | -59.12% |
| Mar 31, 2024 | 9.81% |
| Dec 31, 2023 | 16.94% |
| Sep 30, 2023 | 12.43% |
| Jun 30, 2023 | 32.34% |
| Mar 31, 2023 | 6.32% |
| Dec 31, 2022 | -8.22% |
| Sep 30, 2022 | -10.71% |
| Jun 30, 2022 | 57.91% |
| Mar 31, 2022 | -201.12% |
| Dec 31, 2021 | -97.35% |
| Sep 30, 2021 | -216.00% |
| Jun 30, 2021 | -1,046.77% |